A study to assess the efficacy and safety of multiple dose levels of AZD7594 administered once daily by inhalation in asthmatic subjects

Study identifier:D3741C00007

ClinicalTrials.gov identifier:NCT03622112

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b Randomised, Double Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

Study drug

AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)

Sex

All

Actual Enrollment

808

Study type

Interventional

Age

18 Years - 85 Years

Date

Study Start Date: 02 Jan 2019

Primary Completion Date: 30 Sept 2019

Study Completion Date: 30 Sept 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2020 by AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria

Inclusion Criteria

1. Provision of informed consent prior to any study-specific procedures
2. Men and women 18 to 85 years of age, inclusive, with body mass index (BMI)≤35
3. Subjects need to be non-smokers or ex-smokers (have quit e cigarettes or other inhaled tobacco products ≥6 months before Visit 1) with a total smoking history of less than 10 pack-years (not applicable for e cigarettes)
4. Documented clinical diagnosis of asthma for ≥6 months before Visit 1
5. Subjects on stable medium to high dose ICS (equivalent of budesonide >400 μg/day) or low to medium dose ICS/LABA for at least 4 weeks prior to screening (Visit 1) (Appendix A, GINA, 2018)
6. Subjects must demonstrate reversibility to inhaled bronchodilators at Visit 2 (a ≥12% and ≥200 mL improvement in FEV1 after administration of a 4 puffs of salbutamol/albuterol)
7. Pre-bronchodilator FEV1 at Visit 3 between 40% and 90% predicted at either −45 or −15 minutes pre-dose
8. At Visit 3, subjects need to be symptomatic on low dose ICS as evidenced by combined daily asthma mean symptom score of >1 over the previous 7 days or SABA use on ≥3 of the last 7 days during the Run-in Period
9. Demonstrate the ability to use the study inhalation device properly
10. Subject able to perform acceptable pulmonary function testing for FEV1 according to American Thoracic Society/European Respiratory Society (ATS/ERS) acceptability criteria
11. Subject is willing and able to follow study procedures and restrictions. Women of child bearing potential (WOCBP) should be stable on their chosen method of highly effective birth control for a minimum of 3 months prior to Visit 1, and willing to use that for the entire duration of the study (from the time they sign the informed consent), and for 1 month after the last dose of IP
12. For optional inclusion in the Gx component of the study, subjects must provide separate informed consent for the genomic sampling and analysis

Exclusion Criteria

1. Known or suspected hypersensitivity to any of the IPs, including budesonide, or excipients, including lactose
2. Systemic steroid use within the 6 weeks before Visit 1
3. Concomitant chronic respiratory disease (including current sleep apnea)
4. History or clinical suspicion of any clinically relevant or active disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject’s ability to participate in the study, or any other safety concerns in the opinion of the Investigator
5. Use of prohibited medications that cannot be stopped during the entire period of the study (starting Visit 1).
6. Subjects with <80% eDiary compliance during Run in Period at Visit 3
7. ACQ-5 of ≥3 at Visit 1, Visit 2, or Visit 3
8. Daily rescue use of SABA ≥12 puffs for ≥3 consecutive days at any time during Run-in Period, before randomisation
9. Any clinically important abnormalities in rhythm, conduction or morphology of the digital ECG at rest and any abnormalities in the digital ECG (at Visit 1 or Visit 3) that, as considered by the Investigator, may interfere with the interpretation of QT interval corrected (QTc) interval changes
10. Prolonged QT interval corrected using Fridericia’s formula (QTcF) ≥450 msec based on ECG at Visit 1 or Visit 3; or family history of long QT syndrome
11. PR (PQ) interval prolongation (>240 msec), intermittent second or third degree atrial-ventricular (AV) block or AV dissociation at Visit 1 or Visit 3
12. Subjects with implantable cardiac defibrillator and subjects with sustained symptomatic ventricular and/or atrial tachyarrhythmia
13. Subjects with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society Class II, or a myocardial infarction or stroke within 6 months before Visit 1
14. History of hospitalisation within 12 months before Visit 1 caused by heart failure or a diagnosis of heart failure higher than New York Heart Association Class II
15. Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) at Visit 1
16. Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1
17. Suspected poor capability to follow instructions of the study, as judged by the Investigator
18. Previous participation or prior screen failure in the current study, or participation in any other research study within 1 month prior to Visit 1
19. Subject under treatment with biologicals such as monoclonal antibodies or chimeric biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5 half-lives before Visit 1, whichever is longer
20. Subject treated with any investigational drug within 30 days (or 5 half-lives, whichever is longer) prior to Visit 1
21. Positive drug screening result that cannot be justified by subject’s medical history and its relevant treatment (over-the-counter product or a valid prescription), or history of or current alcohol or drug abuse (including marijuana and marijuana-containing valid prescriptions), as judged by the Investigator
22. Planned in-patient surgery, major dental procedure or hospitalisation during the study
23. Pregnant woman or lactating woman
24. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, contract research organisation staff and/or staff at the study centre)
25. Suspicion of Gilbert’s syndrome
26. Vulnerable persons (eg, persons kept in detention)

This is a randomised, placebo-controlled, double-blind multi center (8 countries: Europe, United States [US], South Africa, and Japan) study conducted on 714 subjects (102 subject per arm) with asthma symptomatic on low dose inhaled corticosteroids (ICS). The study consists of 3 periods: - Run-in period (21-28 days; visits 1 to 3) - Treatment period (12-week; Visits 4 to 7) - Follow-up (1-week; visit 8). The Run-in period consist of 3 visits: Screening visit (1), reversibility visit (2) and randomization visit (3). All subjects will sign an informed consent form (ICF) prior to participating in any study-specific procedures. Subjects found to be eligible at Visit 1 (Screening Visit) will discontinue all asthma medications and switch to low dose budesonide (200 μg twice a day [BID] in Europe and 180 μg BID in US) and rescue medication will be taken as needed. Subjects on long-acting beta agonist (LABA), fixed dose combination ICS/LABA treatment or a long-acting muscarinic antagonist (LAMA) will return for Visit 2 between 2 to 7 days after Visit 1 to have a sufficient wash-out time of their asthma medications. If reversibility criteria are met at Visit 2, subjects will proceed to Visit 3 (Randomization will occur within 21 to 28 days of Visit 1). At Visit 3, subjects who remain symptomatic while on low dose budesonide will be randomized in an overall ratio of 1:1:1:1:1:1:1 to one of 7 possible treatments and will receive inhalation powder via oral route: • AZD7594 DPI 55μg [nominal strength]/50 μg [delivered dose] (QD) • AZD7594 DPI 99 μg/90 μg QD • AZD7594 DPI 198 μg/180 μg QD • AZD7594 DPI 396 μg/360 μg QD • AZD7594 DPI 792 μg/720 μg QD • Placebo for AZD7594 QD • FF 100 μg QD (open-label) The follow-up will be done by telephone contact within 7 to 10 days after Visit 7 or last investigational product (IP) intake. The total duration of the study will be between 113 to 135 days for each individual subject and is planned to run approximately 12 months (it should not exceed 18 months).

No locations available

Arms	Assigned Interventions
Experimental: AZD7594 Dose 1 The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.	Drug: AZD7594 DPI 55μg/50μg. A non-steroidal and selective modulator of the GR.
Experimental: AZD7594 Dose 2 The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.	Drug: AZD7594 DPI 99 µg/90 µg A non-steroidal and selective modulator of the GR.
Experimental: AZD7594 Dose 3 The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.	Drug: AZD7594 DPI 198 µg/180 µg A non-steroidal and selective modulator of the GR.
Experimental: AZD7594 Dose 4 The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.	Drug: AZD7594 DPI 396 µg/360 µg once daily. A non-steroidal and selective modulator of the GR.
Experimental: AZD7594 Dose 5 The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.	Drug: AZD7594 DPI 792 µg/720 µg A non-steroidal and selective modulator of the GR.
Placebo Comparator: Placebo The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.	Drug: Placebo for AZD7594 once daily. Placebo for AZD7594
Active Comparator: Fluticasone Furoate The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).	Drug: FF 100 µg once daily (open-label) Fluticasone furoate

Documents available

The CSP redacted.
Download
The SAP redacted.
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Kai Michael Beeh

Insaf – Institut für Atemwegsforschung GmbH, D65187, Germany.